GO
Loading...

GlaxoSmithKline PLC

More

  • UPDATE 1-GlaxoSmithKline abandons sale of older drugs Thursday, 4 Dec 2014 | 12:03 PM ET

    LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers. A spokesman for GSK, which was being advised on the disposal by Lazard, declined to give any more details. People familiar with the situation said last month that several private...

  • GlaxoSmithKline abandons sale of older drugs Thursday, 4 Dec 2014 | 11:28 AM ET

    LONDON, Dec 4- GlaxoSmithKline said on Thursday it had decided not to sell a portfolio of older drugs marketed in North America and Europe after considering offers from potential buyers.

  • Ebola booster vaccine starts first trials in Oxford Thursday, 4 Dec 2014 | 4:25 AM ET

    LONDON, Dec 4- Scientists at Oxford University have launched the first clinical tests of a new Ebola vaccine approach, using a booster developed by Denmark's Bavarian Nordic that may improve the effects of a shot from GlaxoSmithKline. Thirty healthy volunteers in Britain who have already received the experimental Ebola vaccine being developed by GSK and the...

  • Many posts going at North Carolina research site. LONDON, Dec 3- GlaxoSmithKline said on Wednesday it would shed "several hundred" U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina...

  • LONDON, Dec 3- GlaxoSmithKline confirmed on Wednesday it would shed several hundred U.S. commercial jobs and a similar number of research positions as it restructures operations in its biggest market, where drug sales are flagging. Many of the jobs lost will be from GSK's Research Triangle Park site in North Carolina as drug research is consolidated in...

  • GSK to ax US jobs in major cost cuts: Sources Monday, 1 Dec 2014 | 2:11 AM ET

    GSK will ax hundreds of U.S. jobs in its biggest market as the drugmaker starts implementing a major cost-saving program.

  • LONDON, Nov 30- GlaxoSmithKline will this week inform U.S. staff of hundreds of job cuts in its biggest market as the drugmaker starts implementing a major cost-saving programme, sources familiar with the matter said on Sunday. Britain's top drugmaker announced at third-quarter results on Oct. 22 that the new restructuring scheme would save 1 billion pounds in...

  • Ebola vaccine from Glaxo passes early safety test Thursday, 27 Nov 2014 | 1:56 AM ET

    An experimental Ebola vaccine made by GlaxoSmithKline caused no serious side effects, scientists reported on Wednesday.

  • WASHINGTON, Nov 26- Switzerland's Novartis AG has agreed to sell its nicotine patch, Habitrol, in order to win U.S. antitrust approval for a consumer healthcare joint venture with Britain's GlaxoSmithKline, the U.S. Federal Trade Commission said on Wednesday. The deal is part of a three-way transaction unveiled in April, which includes GSK buying Novartis'...

  • Nov 24- BioMarin Pharmaceuticals Inc said it would buy Dutch drug developer Prosensa Holding NV for about $840 million, betting on a drug that has potential to become the first approved treatment for a rare muscle disorder. "Though the asset has risk given the clinical history, we believe the payoff for BioMarin could be substantial given the unmet need...

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • Early Movers: UTX, VZ, TSLA, LGF, RNA & more Monday, 24 Nov 2014 | 8:36 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Sanofi's case for experimental drugs in pipeline Wednesday, 19 Nov 2014 | 12:24 PM ET

    After drug company Sanofi removed CEO Chris Viehbacher, investors question the future of the company's growth and future.

  • Nov 18- The estimated average cost of developing an approved new drug has more than doubled to more than $2.5 billion from a 2003 estimate by Tufts University, but critics questioned the figure and noted the school's strong financial ties to the pharmaceutical industry. The Tufts Center for the Study of Drug Development, located in Boston, in 2003 estimated the...

  • LONDON, Nov 17- An experimental lupus drug from AstraZeneca significantly improved the symptoms of lupus in a mid-stage clinical trial, boosting prospects for a medicine the company believes could become a major seller. AstraZeneca's sifalimumab works in a different way to Benlysta by targeting interferon, a protein involved in inflammation.

  • *GlaxoSmithKline again leads index for best drug access. The contradictory advances and the problems facing the industry are evident at GlaxoSmithKline, which retained its long-standing top spot in the index, while simultaneously featuring in a major bribery scandal in China. "Corruption is terrible, but it also takes attention away from the fact that these...

  • DAKAR/ BRUSSELS, Nov 14- Medecins Sans Frontiers "wasted time" by waiting too long to call for vaccines to fight an unprecedented outbreak of Ebola in West Africa, a veteran of the medical charity told Reuters. The group's response to the epidemic which has so far killed more than 5,000 people has been widely praised by governments and the World Health Organization.

  • LONDON, Nov 13- Apollo Global Management is planning to bid for all GlaxoSmithKline's mature drugs, joining an auction expected to value the business at more than $3 billion, according to four people familiar with the process. GSK, Britain's biggest drugmaker, is looking to divest its mature prescription medicine products sold in North America and western...

  • NEW YORK, Nov 9- Now that new medicines promise to cure millions of hepatitis C patients in coming years, drugmakers including Gilead Sciences Inc are turning their attention to other liver diseases, with a potential market that could rival the success of statins, which generated more than $30 billion a year in sales at their peak. Several companies are working on...

  • LONDON, Nov 6- The Europe Union and drugmakers pledged on Thursday to invest 280 million euros in Ebola research, with the lion's share going to the testing and manufacture of potential vaccines. The funding will go to projects backed by the Innovative Medicines Initiative, a public-private scheme jointly paid for by the European Commission and the...